For many investors, the healthcare industry can feel like an unfriendly place. Phase 3 trial failures, patent cliffs, reimbursement negotiations, regulatory curveballs, geopolitical tensions, and sudden shifts in clinical practice can make the sector seem like a minefield reserved only for physicians, scientists, or those who speak in three-letter acronyms. It is easy to understand why many generalists view healthcare as “too complicated” or “too specialised” to underwrite with confidence.

But the truth is more encouraging: there are many ways to invest in the next wave of healthcare value creation without needing to be an MD or understand DNA sequencing. After returning from one of the year’s major global healthcare conferences, where we heard from management teams, operators, and industry specialists across the value chain, we are more confident than ever that the opportunity set is large and attractive.

Below, we outline the themes that stood out — and where investors can participate in the next phase of sector growth while managing the inherent risks.

 

Innovation is broadening — and not just in headline areas

Innovation remains the engine of healthcare, and the breadth of opportunity is wider than expected. The metabolic and obesity category, powered by GLP-1 drugs, continues to dominate headlines and is quickly evolving into a long-term structural theme.

Outside of GLP-1’s, we heard about many other interesting therapies that currently sit outside the usual spotlight:

  • Specialty allergy therapy, where tablet-based immunotherapy is supported by decades of evidence, yet remains massively underpenetrated.
  • Women’s health, spanning contraception, fertility, menopause, and endometriosis — all driven by demographic shifts and historically unmet needs.
  • Targeted biologics and advanced therapeutics, where precision, durability, and long treatment durations support better adoption rates and pricing.

Across these trends, successful innovators share the same attributes: portfolios addressing chronic, under-served conditions; strong clinical data; and long treatment durations that support resilient revenue and economics. No need to pick molecules — success can equally come from identifying business models built on scale, strong data and defensible science and expertise.

 

The “picks and shovels” of healthcare remain critical — and investable

One of the clearest takeaways from the conference was the prominence of the industrial ecosystem behind the science. Behind every therapy sits a network of manufacturers, device engineers, packaging specialists, automation partners, and suppliers of active ingredients. You won’t often find these businesses in the headlines, but they often provide more predictable growth, diversified exposure, and less binary risk.

Several trends emerged:

  • Capacity for complex active ingredients — especially those used in metabolic drugs — remains tight. Growth is supported by multi-year customer commitments and specialised know-how that is difficult to replicate.
  • Demand for pre-filled syringes, device platforms, and ready-to-use packaging continues to accelerate alongside biologics.
  • Lab automation and diagnostics are seeing early signs of recovery as utilisation normalises and labour constraints intensify.
  • Onshoring and localisation trends are reshaping supply chains, creating both challenges and opportunities.

Investors often overlook these “picks and shovels” exposures, but they remain some of the most compelling ways to participate in healthcare’s structural growth without taking clinical trial risk.

 

Risk under our microscope: geopolitics, pricing, and regulation

No discussion of healthcare would be complete without acknowledging the sector’s risks. Executives consistently cited geopolitics and supply chain complexity as top operational concerns. Tariffs, nearshoring, and shifting trade patterns are influencing where capacity is built and how resilient supply chains must become.

Pricing and reimbursement pressure remain front of mind as governments reassess fiscal priorities. Meanwhile, regulatory complexity is rising — all of which increase compliance requirements but also act as barriers to entry.

For investors, the key is not to avoid these risks but to underwrite them intelligently. Companies with diversified supply chains, balanced customer exposure, and strong pricing power are best equipped to navigate this landscape.

 

How to invest behind healthcare’s next cycle

Based on what we heard and saw, several types of businesses stand out as particularly attractive ways to gain exposure:

  • Resilient, recurring revenue models — chronic therapies, diagnostics, services, and software that helps navigate regulatory complexity.
  • The industrial complex — manufacturers, device platforms, drug containment and delivery solutions, and automation specialists positioned to solve production bottlenecks.
  • Under-served niches — allergy, women’s health, personalised medicine — all supported by large patient pools and rising awareness.
  • Businesses with geopolitical and policy resilience — diversified supply chains and the ability to adapt to regulatory changes.

This year’s conversations reinforced a simple truth: value creation in healthcare comes not only from scientific breakthroughs but the ability to turn that science into high quality products that improves patient lives.

 

Bottom line

Healthcare will always appear intimidating from the outside; however, investors can still access healthcare’s growth cycles without needing to decode clinical trial data or memorise complex medical terminology. The key is to focus on business models with resilient revenues, disciplined capital deployment, and strong scientific and manufacturing expertise while minimizing the sector’s idiosyncratic risks.